Best Small Cap Stocks To Keep An Eye On - July 30th

Key Points

• MarketBeat highlights seven small-cap stocks worth watching, including Replimune Group, Sharplink Gaming, and Sarepta Therapeutics, which have displayed significant trading volumes recently.
• The stocks listed have market capitalizations ranging from about $300 million to $2 billion and are recognized for their potential for above-average returns despite higher volatility.
• Replimune Group's lead candidate, RP1, is currently in Phase I/II trials for cancer treatment, showcasing the company's focus on innovative oncolytic immunotherapy.

Replimune Group, Sharplink Gaming, Sarepta Therapeutics, Spring Valley Acquisition, BioNexus Gene Lab, Incannex Healthcare, and BigBear.ai are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively small market capitalizations—typically between about $300 million and $2 billion, though specific cutoffs can vary by index provider. Because these firms are still growing and less established than larger companies, their stock prices tend to be more volatile but also offer the potential for above-average returns. Investors often include small-caps in their portfolios for diversification and the chance of outsized growth, while accepting a higher risk profile. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Replimune Group (REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Shares of REPL stock traded up $3.56 during mid-day trading on Wednesday, hitting $7.31. 189,242,990 shares of the stock were exchanged, compared to its average volume of 3,655,266. The stock's fifty day simple moving average is $9.06 and its two-hundred day simple moving average is $10.13. The stock has a market capitalization of $568.79 million, a price-to-earnings ratio of -2.31 and a beta of 0.61. Replimune Group has a 12-month low of $2.68 and a 12-month high of $17.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95.

Read Our Latest Research Report on REPL

Sharplink Gaming (SBET)

SharpLink Gaming, Inc. operates as an online technology company that connects sports fans, leagues, and sports websites to sports betting and iGaming content. The company operates through four segments: Affiliate Marketing Services United States, Affiliate Marketing Services International, Sports Gaming Client Services, and SportsHub Games Network.

Shares of SBET stock traded up $0.33 during mid-day trading on Wednesday, hitting $19.41. 33,498,485 shares of the stock were exchanged, compared to its average volume of 10,400,833. The stock's fifty day simple moving average is $23.89 and its two-hundred day simple moving average is $11.10. Sharplink Gaming has a 12-month low of $2.26 and a 12-month high of $124.12.

Read Our Latest Research Report on SBET

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Shares of SRPT stock traded up $0.99 during mid-day trading on Wednesday, hitting $16.82. 34,663,054 shares of the stock were exchanged, compared to its average volume of 5,645,826. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $145.00. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -6.31 and a beta of 0.45. The stock's fifty day simple moving average is $25.16 and its two-hundred day simple moving average is $62.52. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02.

Read Our Latest Research Report on SRPT

Spring Valley Acquisition (SV)

Shares of SV traded down $2.02 during mid-day trading on Wednesday, hitting $48.97. 9,449,691 shares of the company's stock were exchanged, compared to its average volume of 530,580. Spring Valley Acquisition has a fifty-two week low of $8.56 and a fifty-two week high of $11.23. The business's 50 day moving average is $37.90 and its two-hundred day moving average is $25.46.

Read Our Latest Research Report on SV

BioNexus Gene Lab (BGLC)

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.

Shares of BGLC traded up $2.82 during mid-day trading on Wednesday, hitting $7.28. 57,272,478 shares of the company's stock were exchanged, compared to its average volume of 1,286,271. BioNexus Gene Lab has a fifty-two week low of $2.01 and a fifty-two week high of $15.60. The business's 50 day moving average is $4.11 and its two-hundred day moving average is $3.51.

Read Our Latest Research Report on BGLC

Incannex Healthcare (IXHL)

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.

Shares of IXHL traded down $0.16 during mid-day trading on Wednesday, hitting $0.91. 392,770,456 shares of the company's stock were exchanged, compared to its average volume of 51,720,770. Incannex Healthcare has a fifty-two week low of $0.08 and a fifty-two week high of $3.12. The firm has a market capitalization of $26.73 million, a P/E ratio of -0.75 and a beta of 7.47. The business's 50 day moving average is $0.35 and its two-hundred day moving average is $0.79.

Read Our Latest Research Report on IXHL

BigBear.ai (BBAI)

BigBear.ai Holdings, Inc. provides artificial intelligence-powered decision intelligence solutions. It offers national security, supply chain management, and digital identity and biometrics solutions. The company also provides data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics, and predictive visualization solutions and services.

Shares of BBAI traded down $0.24 during mid-day trading on Wednesday, hitting $6.39. 51,574,885 shares of the company's stock were exchanged, compared to its average volume of 88,544,125. BigBear.ai has a fifty-two week low of $1.16 and a fifty-two week high of $10.36. The firm has a market capitalization of $1.86 billion, a P/E ratio of -8.21 and a beta of 3.46. The business's 50 day moving average is $5.56 and its two-hundred day moving average is $4.65. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.55.

Read Our Latest Research Report on BBAI